Heart failure (HF) is a major healthcare problem. In patients with Heart Failure with Reduced Ejection Fraction (HFrEF), aldosterone antagonists reduce mortality and hospitalization rate. Gender-related differences have been described in the regulation of renin angiotensin aldosterone system (RAAS), which is at the core of the pathophysiology of HF. Regarding gender-related differences in the use of MRAs, less is known about the effects of androgens on RAAS. In this single-center prospective cohort, a total of 100 adult (≥ 18 years) ambulatory patients of both sexes with the diagnosis of HF with HFrEF (LVEF≤ 40%) and NYHA class II-IV under optimized medical therapy started an aldosterone antagonist are enrolled and followed-up for 6 months. Patients are categorized according to their apparent sexual gender into two groups: the male group and the female group.
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Heart failure hospitalization
Timeframe: 6 months after enrollment
Acute myocardial infarction
Timeframe: 6 months after enrollment
Percentage of patients who discontinued mineralocorticoid receptor antagonist
Timeframe: 6 months after enrollment
Switching from one mineralocorticoid receptor antagonist to another
Timeframe: 6 months after enrollment
Acute Kidney Injury
Timeframe: 6 months after enrollment
Adverse effects
Timeframe: 6 months after enrollment